Longer-Term DME Data Bolster Optimism Around Mechanism For Unity’s UBX1325

24 Apr 2023

• By Alaric DeArment

The company announced 48-week, Phase IIa data for the drug in diabetic macular edema, an update from 24-week data the company announced in November.

Unity announced Phase IIa follow-up data in diabetic macular edema for UBX1325 • Source: Shutterstock

More from Clinical Trials

More from R&D